View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMETabolic EXplorer 배당 및 자사주 매입배당 기준 점검 0/6METabolic EXplorer 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-129.9%자사주 매입 수익률총 주주 수익률-129.9%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares IndexNew Risk • Sep 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Revenue has declined by 36% over the past year. Market cap is less than US$10m (€6.16m market cap, or US$6.87m).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).분석 기사 • Feb 10METabolic EXplorer S.A. (EPA:METEX) Surges 28% Yet Its Low P/S Is No Reason For ExcitementThose holding METabolic EXplorer S.A. ( EPA:METEX ) shares would be relieved that the share price has rebounded 28% in...분석 기사 • Dec 18Why Investors Shouldn't Be Surprised By METabolic EXplorer S.A.'s (EPA:METEX) 27% Share Price PlungeTo the annoyance of some shareholders, METabolic EXplorer S.A. ( EPA:METEX ) shares are down a considerable 27% in the...New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.분석 기사 • Oct 01Health Check: How Prudently Does METabolic EXplorer (EPA:METEX) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).분석 기사 • Jul 30News Flash: One METabolic EXplorer S.A. (EPA:METEX) Analyst Has Been Trimming Their Revenue ForecastsThe latest analyst coverage could presage a bad day for METabolic EXplorer S.A. ( EPA:METEX ), with the covering...Major Estimate Revision • Jul 29Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €235.0m to €200.0m. EPS estimate unchanged from -€0.44 per share at last update. Chemicals industry in France expected to see average net income growth of 3.5% next year. Consensus price target of €1.20 unchanged from last update. Share price fell 13% to €0.97 over the past week.Major Estimate Revision • Jun 14Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.40 to -€0.35 per share. Revenue forecast unchanged from €235.0m at last update. Chemicals industry in France expected to see average net income growth of 7.6% next year. Consensus price target of €1.20 unchanged from last update. Share price rose 5.1% to €1.07 over the past week.Major Estimate Revision • Jan 06Consensus EPS estimates fall by 133%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €242.1m to €232.7m. Losses expected to increase from €0.39 per share to €0.91. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target down from €1.85 to €1.60. Share price rose 6.0% to €1.28 over the past week.Price Target Changed • Nov 16Price target decreased to €1.85Down from €2.70, the current price target is provided by 1 analyst. New target price is 14% above last closing price of €1.62. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.39 compared to earnings per share of €2.31 last year.Major Estimate Revision • Oct 07Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €290.6m to €264.3m. Losses expected to increase from €0.30 per share to €0.38. Chemicals industry in France expected to see average net income growth of 19% next year. Consensus price target down from €2.70 to €1.94. Share price fell 4.4% to €1.51 over the past week.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.Major Estimate Revision • Sep 22Consensus EPS estimates fall by 15%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €298.3m to €290.6m. Losses expected to increase from €0.26 per share to €0.30. Chemicals industry in France expected to see average net income growth of 0.1% next year. Consensus price target of €2.70 unchanged from last update. Share price fell 19% to €1.67 over the past week.분석 기사 • Jul 10Downgrade: The Latest Revenue And EPS Forecasts For METabolic EXplorer S.A. (EPA:METEX)Market forces rained on the parade of METabolic EXplorer S.A. ( EPA:METEX ) shareholders today, when the covering...Major Estimate Revision • Jul 09Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €355.8m to €298.3m. Forecast loss of -€0.26, down from profit of €0.30 per share profit previously. Chemicals industry in France expected to see average net income growth of 0.8% next year. Consensus price target down from €10.50 to €2.85. Share price fell 10% to €1.79 over the past week.분석 기사 • Jun 14Does METabolic EXplorer (EPA:METEX) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • May 10Is METabolic EXplorer S.A. (EPA:METEX) Potentially Undervalued?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a double-digit share price rise of...Price Target Changed • Apr 27Price target increased to €10.50Up from €7.80, the current price target is provided by 1 analyst. New target price is 92% above last closing price of €5.48. Stock is up 5.7% over the past year.Reported Earnings • Apr 02Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 107%, compared to a 13% growth forecast for the industry in France.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.05, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Chemicals industry in France. Total returns to shareholders of 189% over the past three years.분석 기사 • Jan 25What Is METabolic EXplorer S.A.'s (EPA:METEX) Share Price Doing?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a decent share price growth in the...Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to €6.16, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 19x in the Chemicals industry in France. Total returns to shareholders of 258% over the past three years.분석 기사 • Oct 06Statutory Earnings May Not Be The Best Way To Understand METabolic EXplorer's (EPA:METEX) True PositionWe didn't see METabolic EXplorer S.A.'s ( EPA:METEX ) stock surge when it reported robust earnings recently. We decided...분석 기사 • May 12METabolic EXplorer (EPA:METEX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).분석 기사 • Mar 18The METabolic EXplorer (EPA:METEX) Share Price Has Soared 428%, Delighting Many ShareholdersWhile some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...Is New 90 Day High Low • Mar 02New 90-day high: €4.82The company is up 118% from its price of €2.21 on 01 December 2020. The French market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 8.0% over the same period.Is New 90 Day High Low • Feb 09New 90-day high: €3.13The company is up 84% from its price of €1.70 on 10 November 2020. The French market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Jan 23New 90-day high: €2.95The company is up 68% from its price of €1.76 on 23 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.Is New 90 Day High Low • Jan 05New 90-day high: €2.87The company is up 71% from its price of €1.68 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 04New 90-day high: €2.58The company is up 41% from its price of €1.83 on 04 September 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.분석 기사 • Dec 03Investors Who Bought METabolic EXplorer (EPA:METEX) Shares A Year Ago Are Now Up 74%The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...Is New 90 Day High Low • Nov 19New 90-day high: €1.89The company is up 5.0% from its price of €1.80 on 20 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 14New 90-day low: €1.62The company is down 16% from its price of €1.92 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 1.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 METEX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: METEX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장METabolic EXplorer 배당 수익률 vs 시장METEX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (METEX)n/a시장 하위 25% (FR)1.9%시장 상위 25% (FR)5.6%업계 평균 (Chemicals)2.2%분석가 예측 (METEX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 METEX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 METEX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 METEX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: METEX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YFR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/10/09 19:08종가2024/10/09 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스METabolic EXplorer S.A.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Arsene GuekamCIC Market Solutions (ESN)Nicolas RoyotPortzamparc BNP ParibasChristophe Dombu YoutaPortzamparc BNP Paribas
공시 • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares Index
New Risk • Sep 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Revenue has declined by 36% over the past year. Market cap is less than US$10m (€6.16m market cap, or US$6.87m).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).
분석 기사 • Feb 10METabolic EXplorer S.A. (EPA:METEX) Surges 28% Yet Its Low P/S Is No Reason For ExcitementThose holding METabolic EXplorer S.A. ( EPA:METEX ) shares would be relieved that the share price has rebounded 28% in...
분석 기사 • Dec 18Why Investors Shouldn't Be Surprised By METabolic EXplorer S.A.'s (EPA:METEX) 27% Share Price PlungeTo the annoyance of some shareholders, METabolic EXplorer S.A. ( EPA:METEX ) shares are down a considerable 27% in the...
New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.
분석 기사 • Oct 01Health Check: How Prudently Does METabolic EXplorer (EPA:METEX) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).
분석 기사 • Jul 30News Flash: One METabolic EXplorer S.A. (EPA:METEX) Analyst Has Been Trimming Their Revenue ForecastsThe latest analyst coverage could presage a bad day for METabolic EXplorer S.A. ( EPA:METEX ), with the covering...
Major Estimate Revision • Jul 29Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €235.0m to €200.0m. EPS estimate unchanged from -€0.44 per share at last update. Chemicals industry in France expected to see average net income growth of 3.5% next year. Consensus price target of €1.20 unchanged from last update. Share price fell 13% to €0.97 over the past week.
Major Estimate Revision • Jun 14Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.40 to -€0.35 per share. Revenue forecast unchanged from €235.0m at last update. Chemicals industry in France expected to see average net income growth of 7.6% next year. Consensus price target of €1.20 unchanged from last update. Share price rose 5.1% to €1.07 over the past week.
Major Estimate Revision • Jan 06Consensus EPS estimates fall by 133%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €242.1m to €232.7m. Losses expected to increase from €0.39 per share to €0.91. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target down from €1.85 to €1.60. Share price rose 6.0% to €1.28 over the past week.
Price Target Changed • Nov 16Price target decreased to €1.85Down from €2.70, the current price target is provided by 1 analyst. New target price is 14% above last closing price of €1.62. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.39 compared to earnings per share of €2.31 last year.
Major Estimate Revision • Oct 07Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €290.6m to €264.3m. Losses expected to increase from €0.30 per share to €0.38. Chemicals industry in France expected to see average net income growth of 19% next year. Consensus price target down from €2.70 to €1.94. Share price fell 4.4% to €1.51 over the past week.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.
Major Estimate Revision • Sep 22Consensus EPS estimates fall by 15%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €298.3m to €290.6m. Losses expected to increase from €0.26 per share to €0.30. Chemicals industry in France expected to see average net income growth of 0.1% next year. Consensus price target of €2.70 unchanged from last update. Share price fell 19% to €1.67 over the past week.
분석 기사 • Jul 10Downgrade: The Latest Revenue And EPS Forecasts For METabolic EXplorer S.A. (EPA:METEX)Market forces rained on the parade of METabolic EXplorer S.A. ( EPA:METEX ) shareholders today, when the covering...
Major Estimate Revision • Jul 09Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €355.8m to €298.3m. Forecast loss of -€0.26, down from profit of €0.30 per share profit previously. Chemicals industry in France expected to see average net income growth of 0.8% next year. Consensus price target down from €10.50 to €2.85. Share price fell 10% to €1.79 over the past week.
분석 기사 • Jun 14Does METabolic EXplorer (EPA:METEX) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
분석 기사 • May 10Is METabolic EXplorer S.A. (EPA:METEX) Potentially Undervalued?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a double-digit share price rise of...
Price Target Changed • Apr 27Price target increased to €10.50Up from €7.80, the current price target is provided by 1 analyst. New target price is 92% above last closing price of €5.48. Stock is up 5.7% over the past year.
Reported Earnings • Apr 02Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 107%, compared to a 13% growth forecast for the industry in France.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.05, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Chemicals industry in France. Total returns to shareholders of 189% over the past three years.
분석 기사 • Jan 25What Is METabolic EXplorer S.A.'s (EPA:METEX) Share Price Doing?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a decent share price growth in the...
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to €6.16, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 19x in the Chemicals industry in France. Total returns to shareholders of 258% over the past three years.
분석 기사 • Oct 06Statutory Earnings May Not Be The Best Way To Understand METabolic EXplorer's (EPA:METEX) True PositionWe didn't see METabolic EXplorer S.A.'s ( EPA:METEX ) stock surge when it reported robust earnings recently. We decided...
분석 기사 • May 12METabolic EXplorer (EPA:METEX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
분석 기사 • Mar 18The METabolic EXplorer (EPA:METEX) Share Price Has Soared 428%, Delighting Many ShareholdersWhile some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
Is New 90 Day High Low • Mar 02New 90-day high: €4.82The company is up 118% from its price of €2.21 on 01 December 2020. The French market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Feb 09New 90-day high: €3.13The company is up 84% from its price of €1.70 on 10 November 2020. The French market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Jan 23New 90-day high: €2.95The company is up 68% from its price of €1.76 on 23 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: €2.87The company is up 71% from its price of €1.68 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 04New 90-day high: €2.58The company is up 41% from its price of €1.83 on 04 September 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.
분석 기사 • Dec 03Investors Who Bought METabolic EXplorer (EPA:METEX) Shares A Year Ago Are Now Up 74%The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Is New 90 Day High Low • Nov 19New 90-day high: €1.89The company is up 5.0% from its price of €1.80 on 20 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 14New 90-day low: €1.62The company is down 16% from its price of €1.92 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 1.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.